Search results
Results From The WOW.Com Content Network
70839 Ensembl ENSG00000169313 ENSMUSG00000036353 UniProt Q9H244 Q9CPV9 RefSeq (mRNA) NM_176876 NM_022788 NM_027571 NM_001357007 NM_001357008 NM_001357010 RefSeq (protein) NP_073625 NP_795345 NP_081847 NP_001343936 NP_001343937 NP_001343939 Location (UCSC) Chr 3: 151.34 – 151.38 Mb Chr 3: 59.12 – 59.17 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse P2Y 12 is a chemoreceptor for ...
Prasugrel, sold under the brand names Effient and Efient, is a medication used to prevent formation of blood clots.It is a platelet inhibitor and an irreversible antagonist of P2Y 12 ADP receptors and is of the thienopyridine drug class.
P2Y 12 structure as generated by PYMOL with color-coded helices. P2Y receptors are membrane proteins belonging to the class A family of G protein-coupled receptors (GPCRs). [5] [6] P2Y receptor proteins display large-scale structural domains typical of GPCRs, consisting of seven hydrophobic transmembrane helices connected by three short extracellular loops and three variably sized ...
Adenosine diphosphate receptor inhibitors are a drug class of antiplatelet agents, used in the treatment of acute coronary syndrome (ACS) or in preventive treatment for patients who are in risk of thromboembolism, myocardial infarction or a stroke.
ADP interacts with a family of ADP receptors found on platelets (P2Y1, P2Y12, and P2X1), which leads to platelet activation. [14] P2Y1 receptors initiate platelet aggregation and shape change as a result of interactions with ADP. P2Y12 receptors further amplify the response to ADP and draw forth the completion of aggregation.
Ticagrelor (Brilinta) is often listed with thienopyridine inhibitors and has similar indications for use but is not a thienopyridine. It is a cyclo-pentyltriazolo-pyrimidine that is distinct from the mechanism of the thienopyridines in that it reversibly (rather than irreversibly) inhibits the P2Y 12 receptor.
Ticlopidine is a tetrahydro-thienopyridine which, when metabolized by the body, irreversibly blocks the P2Y12 component of the ADP receptor on the surface of platelets. Without ADP, fibrinogen does not bind to the platelet surface, preventing platelets from sticking to each other. [ 1 ]
Cangrelor, sold under the brand name Kengreal among others, is a P2Y 12 inhibitor FDA approved as of June 2015 as an antiplatelet drug [5] for intravenous application. Some P2Y 12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. [5]